Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation

Fig. 4

TRPM7 silencing enhances the AMPK activation, which is associated with inhibiting glycolysis in ovarian cancer cells. A Western blot and IHC analyses of HIF-1α expression and AMPK phosphorylation in the indicated cells and xenograft SKOV3 tumors (scale bar = 50 μm). B, C, F Treatment with CC to inhibit AMPK activation enhanced glycolysis, which was mitigated by HIF-1α silencing, by measuring glucose uptake (B), lactic acid production (C) and ECAR (F) in SKOV3-sh-control, SKOV3-sh-TRPM7, HO8910-sh-control and HO8910-sh-TRPM7 cells. D, E, G Treatment with metformin to enhance the AMPK activation attenuated glycolysis, which was abrogated by HIF-1α over-expression, by measuring glucose uptake (D), lactic acid production (E) and ECAR (G) in the indicated cells

Back to article page